Obinutuzumab (Gazyvaro®) for Follicular Lymphoma

Assessment Status Assessment process complete
Drug Obinutuzumab
Brand Gazyvaro®
Indication In combination with bendamustine followed by obinutuzumab maintenance for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
Assessment Process
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 26/07/2016
NCPE assessment completed 25/01/2017
NCPE assessment outcome Reimbursement not recommended at the submitted price

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.